Polatuzumab vedotin (Polivy®) in combination with bendamustine and rituximab is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant (HSCT).
| NCPE Assessment Process | Ongoing |
| Rapid Review commissioned | 03/12/2019 |
| Rapid Review completed | 27/01/2020 |
| Rapid Review Outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of polatuzumab vedotin (Polivy®) compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by the HSE | 26/02/2020 |
| Pre-submission consultation with Applicant | 31/03/2020 |
| Current status | Awaiting HTA submission from Applicant |